IL-2/Anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8+ T cell responses and increases the ratio of effector/memory CD8+ T cells to regulatory T cells

Journal of Immunology

Volumn 180, Issue 7, 2008, Pages 5118-5129

  Mostböck, Sven ^a   Christine Lutsiak, M E ^a   Milenic, Diane E ^a   Baidoo, Kwamena ^a   Schlom, Jeffrey ^a   Sabzevari, Helen ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 2 ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE; ANTIGEN; GAMMA INTERFERON; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL POPULATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNE SYSTEM; MEMORY T LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; CYTOLOGY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; TIME;

ANIMALS; ANTIBODIES; ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, NATURAL; MICE; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; VACCINES;

EID: 44449145525     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.7.5118     Document Type: Article

References (45)

1. Waldmann, T. A. 2006. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6: 595-601.
2. + memory T cells. Nature 441: 890-893.
3. + T cells increases the size of the acute antiviral response and of the resulting memory T cell pool. J. Immunol. 169: 4990-4997.
4. Blattman, J. N., J. M. Grayson, E. J. Wherry, S. M. Kaech, K. A. Smith, and R. Ahmed. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9: 540-547.
5. Boyman, O., M. Kovar, M. P. Rubinstein, C. D. Surh, and J. Sprent. 2006. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311: 1924-1927.
6. Liu, Z., Q. Liu, H. Hamed, R. M. Anthony, A. Foster, F. D. Finkelman, J. F. Urban, Jr., and W. C. Gause. 2005. IL-2 and autocrine IL-4 drive the in vivo development of antigen-specific Th2 T cells elicited by nematode parasites. J. Immunol. 174: 2242-2249.
7. + T cell clones in older mice is controlled by cytokines. J. Immunol. 166:2186 -2193.
8. Ku, C. C., M. Murakami, A. Sakamoto, J. Kappler, and P. Marrack. 2000. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 288:675-678.
9. + T cells. Proc. Natl. Acad. Sci. USA 99: 8832-8837.
10. + T cells. J. Immunol. 173: 6041-6049.
11. Kamimura, D., Y. Sawa, M. Sato, E. Agung, T. Hirano, and M. Murakami. 2006. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J. Immunol. 177: 306 -314.
12. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201:723-735.
13. Sato, J., N. Hamaguchi, K. Doken, S. Iwasa, Y. Ogawa, and H. Toguchi. 1994. Pharmacokinetic alteration in rats of recombinant interleukin-2 (rIL-2) by immu- nocomplexing with a monoclonal antibody against rIL-2. Biol. Pharm. Bull. 17:535-538.
14. Montero-Julian, F. A., B. Klein, E. Gautherot, and H. Brailly. 1995. Pharmaco- kinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 85:917-924.
15. Rosenblum, M. G., B. W. Unger, J. U. Gutterman, E. M. Hersh, G. S. David, and J. M. Frincke. 1985. Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Res. 45: 2421-2424.
16. Jones, A. T., and H. J. Ziltener. 1993. Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies. Blood 82: 1133-1141.
17. Martens, E., C. Dillen, W. Put, H. Heremans, J. van Damme, and A. Billiau. 1993. Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen- antibody complexes. Eur. J. Immunol. 23: 2026 -2029.
18. Finkelman, F. D., K. B. Madden, S. C. Morris, J. M. Holmes, N. Boiani, I. M. Katona, and C. R. Maliszewski. 1993. Anti-cytokine antibodies as carrier proteins: prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J. Immunol. 151: 1235-1244.
19. Sato, J., N. Hamaguchi, K. Doken, K. Gotoh, K. Ootsu, S. Iwasa, Y. Ogawa, and H. Toguchi. 1993. Enhancement of anti-tumor activity of recombinant interleu- kin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2. Biotherapy 6: 225-231.
20. Sato, J., N. Hamaguchi, K. Doken, K. Gotoh, K. Ootsu, S. Iwasa, Y. Ogawa, and H. Toguchi. 1994. Enhancement of the anti-tumor activity of recombinant inter- leukin-2 (rIL-2) by immunocomplexing with an F(ab')2 fragment of murine monoclonal antibody against rIL-2. Biol. Pharm. Bull. 17: 1101-1105.
21. Courtney, L. P., J. L. Phelps, and L. M. Karavodin. 1994. An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2. Immunopharmacology 28: 223-232.
22. May, L. T., R. Neta, L. L. Moldawer, J. S. Kenney, K. Patel, and P. B. Sehgal. 1993. Antibodies chaperone circulating IL-6: paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J. Immunol 151: 3225-3236.
23. Krupa, A., H. Kato, M. A. Matthay, and A. K. Kurdowska. 2004. Proinflammatory activity of anti-IL-8 autoantibody:IL-8 complexes in alveolar edema fluid from patients with acute lung injury. Am. J. Physiol. 286: L1105-L1113.
24. Espejo, C., M. Penkowa, I. Saez-Torres, J. Xaus, A. Celada, X. Montalban, and E. M. Martinez-Caceres. 2001. Treatment with anti-interferon-γ monoclonal antibodies modifies experimental autoimmune encephalomyelitis in interferon-y receptor knockout mice. Exp. Neurol. 172: 460 -468.
25. Lidbury, B. A., R. Aston, I. A. Ramshaw, W. B. Cowden, and D. A. Rathjen. 1993. The enhancement of human tumor necrosis factor-α antiviral activity in vivo by monoclonal and specific polyclonal antibodies. Lymphokine Cytokine Res. 12: 69 -74.
26. Lee, V. W., M. H. Coan, and C. J. Galloway. 1992. Conjugated anti-TNF antibodies enhance the binding and degradation of TNF. Biotechnol. Ther. 3: 51-62.
27. Prlic, M., D. Kamimura, and M. J. Bevan. 2007. Rapid generation of a functional NK-cell compartment. Blood 110: 2024-2026.
28. Kamimura, D., and M. J. Bevan. 2007. Naive CD8kin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2. Biotherapy 6: 225-231. T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J. Exp. Med. 204: 1803-1812.
29. Cho, J. H., O. Boyman, H. O. Kim, B. Hahm, M. P. Rubinstein, C. Ramsey, D. M. Kim, C. D. Surh, and J. Sprent. 2007. An intense form of homeostatic proliferation of naive CD8kin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2. Biotherapy 6: 225-231. cells driven by IL-2. J. Exp. Med. 204: 1787-1801.
30. Rubinstein, M. P., M. Kovar, J. F. Purton, J. H. Cho, O. Boyman, C. D. Surh, and J. Sprent. 2006. Converting IL-15 to a superagonist by binding to soluble IL- 15Rα. Proc. Natl. Acad. Sci. USA 103: 9166-9171.
31. Stoklasek, T. A., K. S. Schluns, and L. Lefrancois. 2006. Combined IL-15/IL- 15Rα immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177:6072-6080.
32. Townsend, A. R., J. Rothbard, F. M. Gotch, G. Bahadur, D. Wraith, and A. J. McMichael. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44:959 -968.
33. Mamalaki, C., J. Elliott, T. Norton, N. Yannoutsos, A. R. Townsend, P. Chandler, E. Simpson, and D. Kioussis. 1993. Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen. Dev. Immunol. 3: 159 -174.
34. Norbury, C. C., D. Malide, J. S. Gibbs, J. R. Bennink, and J. W. Yewdell. 2002. Visualizing priming of virus-specific CD8kin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2. Biotherapy 6: 225-231. T cells by infected dendritic cells in vivo. Nat. Immunol. 3: 265-271.
35. Hodge, J. W., H. Sabzevari, A. G. Yafal, L. Gritz, M. G. Lorenz, and J. Schlom. 1999. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59: 5800 -5807.
36. Reali, E., D. Canter, H. Zeytin, J. Schlom, and J. W. Greiner. 2005. Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine 23: 2909 -2921.
37. Brechbiel, M., and O. Gansow. 1992. Synthesis of C-functionalized trans-cyclo- hexyldiethylenetriaminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212-particle emitter. J. Chem. Soc. Perkin Trans. 1 1173-1178.
38. Milenic, D., K. Garmestani, E. Dadachova, L. Chappell, P. Albert, D. Hill, J. Schlom, and M. Brechbiel. 2004. Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother. Radiopharm. 19: 135-147.
39. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
40. Pippin, C. G., T. A. Parker, T. J. McMurry, and M. W. Brechbiel. 1992. Spec- trophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug. Chem. 3: 342-345.
41. Donohue, J. H., and S. A. Rosenberg. 1983. The fate of interleukin-2 after in vivo administration. J. Immunol. 130: 2203-2208.
42. Fukuhara, H., A. Matsumoto, T. Kitamura, and T. Takeuchi. 2006. Neutralization of interleukin-2 retards the growth of mouse renal cancer. BJU Int. 97:1314-1321.
43. Zhang, H., K. S. Chua, M. Guimond, V. Kapoor, M. V. Brown, T. A. Fleisher, L. M. Long, D. Bernstein, B. J. Hill, D. C. Douek, et al. 2005. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4kin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2. Biotherapy 6: 225-231.CD25kin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2. Biotherapy 6: 225-231. regulatory T cells. Nat. Med. 11: 1238 -1243.
44. + regulatory T cells in cancer patients. Blood 107:2409 -2414.
45. Chang, A. E., and S. A. Rosenberg. 1989. Overview of interleukin-2 as an im- munotherapeutic agent. Semin. Surg. Oncol. 5: 385-390.